Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Extension of ARENA 2 Evaluating Long-Term Safety and Efficacy of ADV7103 in Primary Distal Renal Tubular Acidosis
2018-004418-16Phase 3Terminated
- Sponsor
- Advicenne
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of Sibnayal in Primary Distal Renal Tubular Acidosis (dRTA) and renal tubular acidosis (RTA), sponsored by Advicenne. Primary endpoint: Treatment-related adverse events. Started Sep 2019; status: terminated.
02
Drugs
Sibnayal
03
Conditions
Primary Distal Renal Tubular Acidosis (dRTA)renal tubular acidosis (RTA)
Beyond the preview
Go deeper on 2018-004418-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004418-16.